News | Contrast Media | February 04, 2016

Imaging probes can be sprayed on cancerous tissue rather than delivered via IV, speeding FDA approval time and immediately alerting surgeons if all cancer cells have been removed

February 4, 2016 — Akrotome Imaging Inc. received a major award from the National Institutes of Health (NIH) in November to complete development and commercialization of its new imaging platform.

The $1.7M grant will fund the development of an imaging instrument and a fluorescent molecular probe that “lights up” many kinds of previously invisible cancer cells, making it easier for surgeons to determine if all cancer cells have been removed or if additional surgeries are required.

Instead of requiring patients to receive large doses of probe via IV hours before the procedure, Akrotome developed something that could be easily sprayed on the tumor area to reveal traces of remaining cancer cells. Results are available in minutes and the patient does not need to be injected with probe.

While the probes can also be administered via IV, the external and topical applications of the probes mean they have fewer U.S. Food and Drug Administration (FDA) regulatory hurdles than competing probes and can reach the market faster and at a much lower cost.

Akrotome has a portfolio of probes that target cathepsins, cancer-associated enzymes that are expressed by 85 percent of solid tumors. Trials conducted by the company indicate the probe can highlight cancer cells with better than 95 percent accuracy. The probes and technologies were developed in the laboratories of Matthew Bogyo, Ph.D., at Stanford University and James Basilion, Ph.D., at Case Western Reserve University, with imaging capabilities provided by Indec Systems Inc.

Akrotome is currently moving its probes forward for use in skin and breast cancers. Future targets include colon, ovarian and lung tumors.

Research is supported by the National Cancer Institute of the National Institutes of Health under Award Number 2R44CA180296-02.


Related Content

Feature | Contrast Media Injectors | By Christine Book

The vital, and growing role of contrast media, and the medical devices employed to inject the agent into the body ...

Time January 19, 2023
arrow
News | Radiology Business

January 18, 2023 — Addressing the growing demand for medical imaging and a shortage of radiologists, Bayer announced the ...

Time January 18, 2023
arrow
News | Contrast Media

December 5, 2022 — Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., has announced results from a ...

Time December 05, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

December 5, 2022 — -Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a ...

Time December 05, 2022
arrow
News | RSNA

December 3, 2022 — Results from its Orviglance Food Effect study were presented by Ascelia Pharma, a biopharmaceutical ...

Time December 03, 2022
arrow
News | Contrast Media

November 26, 2022 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a ...

Time November 26, 2022
arrow
News | Computed Tomography (CT)

November 26, 2022 — As international leaders in the field of Imaging gather for the 2022 Radiological Society of North ...

Time November 26, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
Feature | Contrast Media | By Shankar Khatkale

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
News | PET Imaging

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2022
arrow
Subscribe Now